Smoking, Smoking, Tobacco
Conditions
Brief summary
Randomized, double-blind, before-after controlled trial to assess changes in regional brain activation in response to cigarette-related cues from before to after treatment with bupropion (vs placebo).
Interventions
Bupropion 150 mg sustained release
Sponsors
Study design
Masking description
Matching placebo pills
Intervention model description
Randomized, double-blind, before-after controlled trial
Eligibility
Inclusion criteria
* Treatment-seeking cigarette smoker * Meet DSM-IV criteria for nicotine dependence * Negative result on urine test for drug use during screening
Exclusion criteria
* History of any Axis I psychiatric diagnosis other than nicotine dependence * Medical conditions that might affect brain function * Current use of medications that could alter brain function * Pregnancy * Current illicit drug use other than occasional use of marijuana
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Craving ratings | 8 weeks | Participants were instructed to respond from 1 (definitely not) to 5 (definitely) on the question, I crave a cigarette right now, after viewing video cues. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Exhaled carbon monoxide (CO) | 8 weeks | Participants were asked to hold their breath for as long as possible, ideally 15 seconds, then to breathe out slowly into the mouthpiece of a CO monitor, aiming to empty the lungs completely. |
| Cigarettes per day | 8 weeks | Self-reported number of cigarettes smoked daily during the past 7 days \[??\] |
| Fagerström Test for Nicotine Dependence (FTND) | 8 weeks | The FTND contains six items that evaluate the quantity of cigarette consumption, the compulsion to use, and dependence. The yes/no items are scored from 0 to 1 and multiple-choice items are scored from 0 to 3. The items are summed to yield a total score of 0-10. The higher the total Fagerström score, the more intense is the patient's physical dependence on nicotine. |